Simponi

But Merck held onto a significant share of rights to Remicade and a follow-up drug, Simponi, which is better than the worst-case scenario it faced—losing the products entirely.

Rivals Resolve Dispute Over Drug Peter Loftus 2011

& Co. Centocor, the J&J subsidiary that makes Remicade, told Schering-Plough on May 5 that it intends to seek arbitration over the rights to Remicade and a new treatment called Simponi as a result of Merck's proposed $41.1 billion purchase of Schering-Plough, the companies said.

J&J Would End Schering Drug Rights 2009

The injectable medication, called Simponi, is essentially a follow-up to the multibillion-dollar drug Remicade, which is marketed in the United States by Johnson &

news | OS | http://www.ocala.com 2009

The injectable medication called Simponi is essentially a follow-up to the multibillion-dollar drug Remicade, which is marketed in the U.S. by New Brunswick-based J&J and in Europe and other countries by Schering-Plough Corp.

unknown title 2009

The latest quarter included a $500 million payment to J&J as part of a settlement of a dispute over rights to the anti-inflammatory drugs Remicade and Simponi.

Merck's Profit Soars on Lower Charges Peter Loftus 2011

The Simponi recall is the latest in a series of product recalls at J&J due to manufacturing-quality lapses, which have hurt sales and damaged the company's reputation.

J&J Recalls Auto-Injection Products Peter Loftus 2011

Investors were pleased to see Merck still held on to a significant share of rights to Remicade and a follow-up drug, Simponi.

Economic Data Boost Stocks Donna Kardos Yesalavich 2011

The recall affects about 230 Simponi pens in Germany and 165 pens in the U.S. that were distributed beyond the wholesale level.

J&J Recalls Auto-Injection Products Peter Loftus 2011

The company is retaining its rights to market Remicade and Simponi in the U.S., the largest market for the drugs.

Rivals Resolve Dispute Over Drug Peter Loftus 2011

It resolved a two-year dispute with marketing partner Johnson & Johnson over the rights to anti-inflammatory drugs Remicade and Simponi.

Merck's Profit Soars on Lower Charges Peter Loftus 2011